FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine, namely to ophthalmology, and can be used in treatment of eye diseases. The methods under the invention include the introduction of a complement pathway inhibitor with C2a, C3a, C5, C5a, C5b, C7, C8 or C9 inactivation. Also, the methods under the invention concern the inhibition of an alternative complement pathway by introducing Factor H or its functional peptide, or siRNA specific for a complement pathway protein, or nucleic acid coding the complement pathway inhibitor.
EFFECT: use of the inventions allows treating eye diseases due to inactivating the classical and alternative complement pathways.
39 cl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF COMPLEMENT PATHWAY INHIBITORS TO TREAT OCULAR DISEASES | 2010 |
|
RU2583927C2 |
| PREVENTING AND TREATING COMPLEMENT-CAUSED OCULAR PATHOLOGIES | 2008 |
|
RU2522976C2 |
| ILT17 ANTIBODY | 2006 |
|
RU2456298C2 |
| ILT17 ANTIBODY | 2012 |
|
RU2599450C2 |
| METHODS AND COMPOSITIONS FOR TREATMENT OF DEGOS DISEASE | 2011 |
|
RU2570390C2 |
| ANTI-THROMBOTIC AGENT AND HUMANIZED MONOCLONAL ANTIBODY RAISED AGAINST VON WILLEBRAND FACTOR | 1999 |
|
RU2223785C2 |
| C3b ANTIBODIES AND METHODS FOR PREVENTION AND TREATMENT OF COMPLEMENT-RELATED DISORDERS | 2008 |
|
RU2473563C2 |
| NOVEL ANTIBODIES | 2008 |
|
RU2490277C2 |
| ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF | 2012 |
|
RU2658603C2 |
| ANTI-C5a ANTIBODIES AND THEIR APPLICATIONS | 2018 |
|
RU2773779C2 |
